Navigation Links
VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
Date:11/12/2007

SAN FRANCISCO, Nov. 12 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, today announced the expansion of its clinical advisory board. Joining the clinical advisory board's chair, Marc Pfeffer, M.D., Ph.D., Dzau Professor of Medicine, Harvard Medical School, and Senior Physician, Brigham & Women's Hospital in Boston, and Jean-Claude Tardif, M.D., Associate Professor of Medicine, University of Montreal, and Director of Research, Montreal Heart Institute, are Marcelo Di Carli, M.D., Associate Professor of Radiology, and Chief of Nuclear Medicine, Brigham and Women's Hospital; Robert Fenichel, M.D., Ph.D, Former Deputy Division Director, Division of CardioRenal Drug Products, Food and Drug Administration; Peter Libby, M.D., Mallinckrodt Professor of Medicine, and Chief, Cardiovascular Division, Brigham and Women's Hospital; and, Jean-Lucien Rouleau, M.D., Dean, Faculty of Medicine, University of Montreal.

"The addition of these well-respected physicians to VIA's clinical advisory board comes at an important time in our history," said Larry Cohen, Ph.D., president and chief executive officer of VIA. "As we prepare for the release of Phase II clinical trial data in the middle of 2008, our clinical advisory board will provide independent medical, scientific, and regulatory guidance in supporting our efforts to advance VIA-2291 as a treatment of cardiovascular disease."

About VIA-2291

VIA's lead product candidate, VIA-2291, is a small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. VIA-2291 is a potent, selective and reversib
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014. Applied DNA Sciences, ... provides DNA-based authentication and security solutions and services, has ... Life Sciences, a newly created position, with a starting ... lead APDN’s drive to build its business in pharmaceuticals ... customers, provide guidance to APDN’s R&D efforts, and apply ...
(Date:7/30/2014)... July 30, 2014  Dyadic International, Inc. ("Dyadic") ... patented and proprietary technologies are used to discover, ... for the bioenergy, bio-based chemical, biopharmaceutical and industrial ... "Tom" Dubinski as Vice President and Chief Financial ... financial and information technology operations for Dyadic and ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 NCERC ... Athmanathan will present his findings on corn stover ... conference this week in Washington, D.C. , ... Energy conference is a testament to the success ... Caupert said. “Thanks to the foresight and vision ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 LayerBio, Inc., ... completion of its first round of seed financing from ... enable preliminary efforts to develop a novel sustained-release product ... of our investors and their commitment to this important ... LayerBio. "Ophthalmology is one of many areas in which ...
Breaking Biology Technology:Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial ... Net loss for the quarter ended September 30, 2009 improved to ... loss of $37.0 million or $0.40 per share in the third ... improvements to its operating efficiencies as compared to a year ago. ...
... /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG), a biotechnology company ... on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today ... Department of Health and Human Services (HHS) to present ... November 5, 2009 at 2:40 pm (EST) at the ...
... Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), announced ... discussing the Company,s 2009 third quarter results on Tuesday, November ... Chairman & Chief Executive Officer, as well as other members ... the Company. A press release reporting the 2009 third quarter ...
Cached Biology Technology:Nektar Therapeutics Reports Third Quarter 2009 Financial Results 2Nektar Therapeutics Reports Third Quarter 2009 Financial Results 3Nektar Therapeutics Reports Third Quarter 2009 Financial Results 4Nektar Therapeutics Reports Third Quarter 2009 Financial Results 5Nektar Therapeutics Reports Third Quarter 2009 Financial Results 6Nektar Therapeutics Reports Third Quarter 2009 Financial Results 7Nektar Therapeutics Reports Third Quarter 2009 Financial Results 8Nektar Therapeutics Reports Third Quarter 2009 Financial Results 9Nektar Therapeutics Reports Third Quarter 2009 Financial Results 10Medicago to present at the U.S. Department of Health and Human Services' Global Health Security Initiative Workshop 2Advanced Life Sciences to Host 2009 Third Quarter Financial Results Conference Call and Webcast 2
(Date:7/30/2014)... studying the potential effects of climate change on ... on the wrong factors, according to a new ... Conservation Society, University of Queensland, and other organizations. ... science is missing the point when it comes ... of climate change scientists focus on the "direct" ...
(Date:7/30/2014)... a joint venture between The University of Texas at ... Science Center at San Antonio, has selected the winners ... Boice from UTSA and Lei Huang from the Health ... "Novel engineered ferritins for tracking and protecting neural stem ... is focused on finding a treatment for stroke through ...
(Date:7/30/2014)... by Clemson University associate professor Andrew S. Mount, performed ... the way for novel anti-fouling paint for ships and ... applications. , The team,s findings, published in ... of barnacles that attaches to a wide variety of ... acts as an underwater heavy-duty adhesive. , "In previous ...
Breaking Biology News(10 mins):Conservation scientists asking wrong questions on climate change impacts on wildlife 2Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2
... Clemson University assistant professor of engineering and ... National Science Foundation Faculty Early Career Development (CAREER) ... students, decisions to enter engineering fields. Trenor ... theory of social capital to better understand undergraduate ...
... in Spanish . , Increasing calcium intake is ... a study supported in part by the Agricultural Research Service ... to help the body utilize calcium. The study also may ... with this problem. Currently, calcium intake recommendations are not ...
... a bacterium found in about 50% of humans worldwide, can cause ... for F1000 Medicine Reports , Seiji Shiota and Yoshio Yamaoka ... Infection by the H. pylori bacterium can approach ... but many develop problems including stomach ulcers. H. pylori ...
Cached Biology News:Clemson researcher receives grant to study engineering enrollment of women, minorities 2Vitamin D and calcium interplay explored 2Preventing gastric cancer with antibiotics 2